Paying for the Oncotype DX Test
In the United States
All major insurance carriers cover the Oncotype DX test for eligible patients with early-stage invasive breast cancer. Medicare has established coverage for the Oncotype DX test for patients with DCIS (non-invasive) breast cancer, although coverage outside of Medicare will vary by insurance plan.
In all Canadian provinces (British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Quebec, Nova Scotia, PEI, New Brunswick and Newfoundland), the test is publicly funded for patients with early stage node negative breast cancer. The test is also publicly funded for patients with node positive breast cancer (1-3 nodes) in Saskatchewan, Manitoba and Newfoundland. Individual patients also have the option of paying for the test themselves if there is no coverage in their province, or if they do not meet pre-specified provincial eligibility criteria.
For insurance and financial-aid questions, please contact Genomic Health Customer Service: